SEC Form 4 · accession 0001600132-18-000017
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Deborah Quinn
Officer — Chief Medical Officer
Period of report
Jan 12, 2018
Accepted (ET)
Jan 17, 2018 · 4:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 12, 2018 | A | 29,557 | $0.00 | A | 104,611 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.03 | Jan 12, 2018 | A | 100,000 | A | — | Jan 12, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This option was granted on January 12, 2018. This option vests in quarterly installments over a four-year period from the date of grant.